Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab to Delay or Prevent Stage 3 T1D
NCT04729296Phase 2Withdrawn
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2021
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of golimumab in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start Jul 2021; status: withdrawn.
02
Drugs
golimumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04729296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729296.